Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 5, 1999, Pages 623-626

  Placidi, Laurent ^a   Scott, Erika Cretton ^a   Eckoff, Devin ^a   Bynon, Steven ^a   Sommadossi, Jean Pierre ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE; PACLITAXEL;

ANIMAL CELL; ARTICLE; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0032959702     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ben Sira I, Nissenkorn I and Kremer I (1988) Retinopathy of prematurity. Surv Ophtalmol 33:1-16.
2. Brem H, Gresser I, Grosfeld J and Folkman J (1993) The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Ped. Surg. 28:1253-1257.
3. Brem H, Ingber D, Blood CH, Bradley D, Urioste S and Folkman J (1991) Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 42:439-441.
4. Cretton-Scott E, Placidi L, McClure H, Anderson DC and Sommadossi JP (1996) Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl)fumagillol (TNP-470;AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 38:117-122.
5. Figg W, Pluda J, Lush R, Saville M, Wyvill K, Reed E and Yarchoan R (1997) The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91-97.
6. Folkman J (1972) Anti-angiogenesis: New concept for therapy of solid tumor. Ann Surg 175:409-416.
7. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203.
8. Folkman J (1990) What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6.
9. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235:442-447.
10. Gibaldi M (1992) Drug interactions. Ann Phamacother 26:709-713.
11. Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, Nishino N, Nakamura S and Baba S (1995) Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 61:268-271.
12. Levy T, Kudelka A, Verschraegen CF, Edwards CL, Freedman RS, Kaplan A, Kieback D, Steger M, Mante R, Gutterman J, Piamsomboon S, Termrungruanglert W and Kavanagh JJ (1996) A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix (Abstract). American Association of Cancer Research Eighty-Seventh Annual Meeting, April 20-24, 1996, Washington, DC.
13. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K and Uchida A (1995) Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61:148-152.
14. Nicolas F, De Sousa G, Thomas P, Placidi M, Lorenzon G and Rahmani R (1995) Comparative metabolism of 3′-azido-3′-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys and humans. Drug Metab Dispos 23:308-313.
15. Oliver SJ, Banquerigo ML and E. Brahn (1994) Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell. Pharmacol. 157:291-299.
16. Oliver SJ, Cheng TP, Banquerigo ML and Brahn E (1995) Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin; reduction of vascular endothelial growth factor (VEGF). Cell Immunol 166:196-206.
17. Placidi L, Cretton-Scott E, De Sousa G, Rahmani R, Placidi M and Sommadossi JP (1995) Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl)fumagillol (TNP-470;AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res. 55:3036-3042.
18. Placidi L, Cretton-Scott E, De Sousa G, Rahmani R, Placidi M and Sommadossi JP (1997) Interspecies variability of TNP-470 metabolism using primary monkey, rat and dog cultured hepatocytes. Drug Metab Dispos 25:94-99.
19. Saville M, Foli A, Broder S and Yarchoan R (1993) In vitro activity of TNP-470, a novel angiogenesis inhibitor, in Kaposi's sarcoma (KS)-related spindle cell lines (Abstract). J Cell Biochem (Suppl 17E):22.
20. Tanaka T, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Higashida T, H. Koyama, Suganuma Y, Takeushi K and Takahashi T (1995) Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br J Cancer 72:650-653.
21. Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen YN, and Brem H (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920-925.
22. Teicher BA (1994) Therapeutic approaches involving oxygen delivery and antiangiogenic agents (Abstract). American Association of Cancer Research Eighty-Fifth Annual Meeting, April 10-13, 1994, San Francisco, CA.
23. Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, Ikebe M and Kajeji Y (1995) Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 61:732-737.
24. Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. New Engl J Med 324:1-8.
25. Zukiwski A, Gutterman J, Bui C, Sella A, Ellerhorst J, Tu S, Amato R, Figg W, Kilboum R and Logothetis C (1994) Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients (pts) with androgen dependent prostate cancer (AIPCa) (Abstract). American Society of Clinical Oncology Thirtieth Annual Meeting, May 14-17, 1994, Dallas, TX.